FIP/AAPS guidelines to dissolution/in vitro release testing of novel/special dosage forms.
Siewert
Martin
M
Aventis, Frankfurt, Germany. martin.siewert@aventis.com
Dressman
Jennifer
J
Brown
Cynthia K
CK
Shah
Vinod P
VP
D000279:Administration, Cutaneous; D000284:Administration, Oral; D000287:Administration, Topical; D002214:Capsules; D004304:Dosage Forms; D004339:Drug Compounding; D004345:Drug Industry / Q000379:methods*; D007263:Infusions, Parenteral; D013488:Suppositories; D013535:Suspensions; D013607:Tablets
D002214:Capsules; D004304:Dosage Forms; D013488:Suppositories; D013535:Suspensions; D013607:Tablets